Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBIT (2019 - 2025)

Burning Rock Biotech has reported EBIT over the past 7 years, most recently at -$1.7 million for Q4 2025.

  • For Q4 2025, EBIT rose 84.67% year-over-year to -$1.7 million; the TTM value through Dec 2025 reached -$7.7 million, up 84.54%, while the annual FY2025 figure was -$7.7 million, 84.21% up from the prior year.
  • EBIT for Q4 2025 was -$1.7 million at Burning Rock Biotech, up from -$2.3 million in the prior quarter.
  • Over five years, EBIT peaked at -$1.6 million in Q2 2025 and troughed at -$41.4 million in Q1 2022.
  • A 5-year average of -$21.1 million and a median of -$24.1 million in 2023 define the central range for EBIT.
  • Biggest five-year swings in EBIT: tumbled 211.81% in 2021 and later surged 89.65% in 2025.
  • Year by year, EBIT stood at -$39.6 million in 2021, then rose by 20.32% to -$31.5 million in 2022, then grew by 25.69% to -$23.4 million in 2023, then surged by 52.09% to -$11.2 million in 2024, then surged by 84.67% to -$1.7 million in 2025.
  • Business Quant data shows EBIT for BNR at -$1.7 million in Q4 2025, -$2.3 million in Q3 2025, and -$1.6 million in Q2 2025.